Marc G. Ghany
National Institutes of Health · 307 works · 23,637 citations · h-index 73
Top works
- Diagnosis, management, and treatment of hepatitis C: An update # † ‡
- A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis† ‡
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
- Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease
- Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
- Current and Future Therapies for Hepatitis C Virus Infection
- Outcome of Sustained Virological Responders With Histologically Advanced Chronic Hepatitis C†,‡,§,¶
- Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon
- 10-year follow-up after interferon-α therapy for chronic hepatitis C
- Long-term therapy of chronic hepatitis B with lamivudine
- Progression of fibrosis in chronic hepatitis C
- Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
- Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests
- Antiviral drug-resistant HBV
- Complication Rate of Percutaneous Liver Biopsies Among Persons With Advanced Chronic Liver Disease in the HALT-C Trial
- Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C
- Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis†
- Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders
- Serum alpha-fetoprotein levels in patients with advanced hepatitis C: Results from the HALT-C Trial
- The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis†